Board of Directors

Dr. Robert L. Coleman

Chief Scientific Officer, US Oncology Research

Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. Prior to joining the M.D. Anderson faculty in 2004, he served as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center in Dallas. At M.D. Anderson, Dr. Coleman was a Professor and served as the Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research as their Chief Scientific Officer.

Dr. Coleman has authored or coauthored over 700 scientific publications, including over 400 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. In 2019, he received the 2019 APGO-CREOG award for Excellence in Teaching. He is a co-Director for GOG-Partners and serves on the Board of Directors for GOG-Foundation, Inc. He currently serves as President of the International Gynecologic Cancer Society (IGCS) and was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”
team4

Dr Brian Solomivitz

Dr Brian Slomovitz is a board certified gynecologic oncologist at Mount Sinai Medical Center. Dr Slomovitz earned his medical degree at Rutgers University – New Jersey Medical School. He completed his residency in obstetrics and gynecology at New York Presbyterian Hospital – Weill Medical College of Cornell University and a gynecologic oncology fellowship at University of Texas MD Anderson Cancer Center.

He holds a leadership position and runs the endometrial trials for the GOG Foundation (Gynecology Oncology Group, a non-profit organization funded by the National Cancer Institute). Dr Slomovitz has held academic and clinical titles at medical centers across Miami-Dade County, including University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, and Jackson Memorial Hospital. He has published and presented extensively on a variety of topics, including cancer in pregnancy, cervical cancer, endometrial cancer, ovarian cancer, cancer of the vagina, and other obstetric and gynecologic cancers and issues.
team3

Dr Jeffery Kutok

team2
Jeffery Kutok is a physician/scientist and biopharmaceutical executive with over 25 years of experience in clinical practice and scientific research, including an academic appointment as an Associate Professor of Pathology for 15 years at Brigham and Women’s Hospital/Harvard Medical School, where he focused on hematopathology, molecular diagnostics, and translational research, and more recently 12 years in biotech leadership roles, including responsibilities as Chief Scientific Officers at Infinity Pharmaceuticals and Epizyme, Inc. His longstanding interest has been in the mechanistic understanding of cancer cell and immune cell biology as it pertains to the development of novel cancer therapies, and he has focused throughout his career on translating scientific findings from the bench to the bedside and back. He earned his M.D. and Ph.D. from the State University of New York at Stony Brook and did his clinical training in pathology and hematopathology at Brigham and Women's Hospital in Boston.

Mrs Rebecca Mehrwerth

Rebecca (Becca) Mehrwerth serves as the Senior Vice President, Head of Commercial for Epizyme. A proven commercial leader with more than 20 years of experience building commercial teams and leading product launches, Becca previously led the U.S. Customer Engagement team within GlaxoSmithKline’s (GSK) Oncology Business Unit charged with advancing its go-to-market strategy for its newly formed business unit following its acquisition of TESARO. Becca spent four years at TESARO where she held roles of increasing responsibility, from Vice President of U.S. sales, leading the launches of VARUBI®, an oral antiemetic, and ZEJULA®, an oral oncolytic for ovarian cancer to Senior Vice President of U.S. Customer Engagement where she provided strategic guidance over multiple customer facing teams generating more than $200 million in sales. Prior to TESARO, she held various commercial roles of increasing responsibility at Celgene, Abraxis, MGI Pharma, Inc., and Bristol-Myers Squibb.

Becca holds a B.B.A. in Finance from Texas State University. She currently serves as the “Biopharma Executive in Residence” for the University of Minnesota where she mentors and engages directly with biotechnology start-ups, providing support for their products or business ideas, from value propositions to business model development. She is serves on the Client Advisory Council for Compeer Financial – a group dedicated to serving Farm Families in the upper Midwest. She has a deep connection to the oncology community and has served and supported many advocacy organizations both directly and indirectly thru her leadership roles in industry. Becca resides in Minnesota and loves spending time on the farm with her family, including husband Kevin and their two children, Lauren and Max.
team5

Dr. Ursula A. Matulonis

WhatsApp Image 2022-05-09 at 5.03.41 PM
Dr. Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is the first recipient of the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute. She co-leads the Gynecologic Cancer Program within the Dana-Farber/Harvard Cancer Center and the Ovarian Cancer Specialized Program in Research Excellence (SPORE) grant from the National Cancer Institute. Her research focuses on developing new targeted therapies for gynecologic malignancies, with a specific interest in ovarian cancer and endometrial cancer

Dr Shefali Agarwal

Dr Shefali Agarwal is a physician by training, respected biotech industry leader and founder of Cancer Shakti Foundation. Her positions have included President and Chief Executive Officer at Onxeo and Acting Chief Medical and Development officer at Epizyme, Board of Director @ FATE therapeutics, Gritstone Bio, ITB-Med, SABC member @ Imvax.

Dr Agarwal has 20 years of diverse career encompassing the entire requisites of academic medicine and research from clinic to bedside. Dr Agarwal is well published and has authored many peer reviewed articles in various cancer publications (NEJM, Lancet Oncology, et al). She is a passionate cancer researcher and is currently working on various innovative cancer development projects that may advance treatment options for patients. She has contributed or led approval of drugs in multiple tumor types including breast, renal cell, ovarian and lymphoma
team20